MNG692
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.424
- ANGIOGENESIS+0.339
- WNT_BETA_CATENIN_SIGNALING+0.318
- MYC_TARGETS_V2+0.198
- PANCREAS_BETA_CELLS+0.197
- MYOGENESIS+0.183
- APICAL_JUNCTION+0.181
- KRAS_SIGNALING_DN+0.148
- COAGULATION+0.129
- HEDGEHOG_SIGNALING+0.102
Top 10 suppressed
- PROTEIN_SECRETION-0.513
- INTERFERON_ALPHA_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.488
- INTERFERON_GAMMA_RESPONSE-0.444
- TGF_BETA_SIGNALING-0.424
- ANDROGEN_RESPONSE-0.375
- PEROXISOME-0.352
- IL6_JAK_STAT3_SIGNALING-0.349
- HEME_METABOLISM-0.341
- MTORC1_SIGNALING-0.314
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A40C-01A-11R-A239-07 | — | B | 0.840 |
| 2 | SRR1516070 | — | — | 0.818 |
| 3 | SRR6013476 | — | cohortSQ1 | 0.807 |
| 4 | TCGA-21-5782-01A-01R-1635-07 | — | cohortSC | 0.806 |
| 5 | TCGA-AO-A0JL-01A-11R-A056-07 | — | E | 0.797 |
| 6 | SJEPD001536_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.797 |
| 7 | TCGA-AC-A5XU-01A-11R-A28M-07 | — | B | 0.794 |
| 8 | MNG771 | — | — | 0.791 |
| 9 | SRR25617847 | — | C | 0.784 |
| 10 | TCGA-ZF-A9RC-01A-11R-A38B-07 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.424 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.339 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.318 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.198 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.197 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.183 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.181 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.148 | Remibrutinib | — uncovered |
| COAGULATION | 0.129 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.102 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.028 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.012 | Inavolisib | — uncovered |